The REDUCE-IT study evaluated the effects of icosapent ethyl on cardiovascular risk in patients with a history of smoking. In this touchCARDIO interview, we speak with Dr Michael Miller (Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA) to discuss the REDUCE-IT study and n–3 fatty acid supplementation.Â
The abstract entitled ‘Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- Could you give us a brief overview of the REDUCE-IT study and its overall findings? (0:31)
- Why do you think this trial had positive findings when other studies with n–3 fatty acid supplementation have failed? (2:06)
Disclosures: Michael Miller is a consultant for Amarin.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Risk here
Additional Resources: Miller M, Bhatt DL, Steg PG, et al. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. Eur Heart J Cardiovasc Pharmacother. 2022;pvac045. doi: 10.1093/ehjcvp/pvac045
